Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3801 | control group Wiki | 0.35 |
drug1410 | HCFWO Wiki | 0.35 |
drug3169 | Standard Care Plus Monitoring Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
drug2123 | NO intervention planned due to the observational study design - only a diagnostic testing Wiki | 0.35 |
drug711 | Caring Contacts Wiki | 0.35 |
drug3835 | exercise group Wiki | 0.35 |
drug3001 | Saliva specimen Wiki | 0.35 |
drug1313 | Fingerstick Wiki | 0.35 |
drug3073 | Serology for Covid-19 Wiki | 0.35 |
drug3171 | Standard Donor Plasma Wiki | 0.35 |
drug1250 | Exposure to telemedicine, after the onset of the pandemic Wiki | 0.35 |
drug2145 | Nasal Swab Wiki | 0.35 |
drug1304 | Fenofibrate Wiki | 0.35 |
drug3412 | Throat swab Wiki | 0.25 |
drug3560 | Usual care Wiki | 0.20 |
drug367 | BCG vaccine Wiki | 0.18 |
drug425 | Best Practice Wiki | 0.16 |
drug2152 | Nasopharyngeal swab Wiki | 0.13 |
drug884 | Convalescent Plasma Wiki | 0.07 |
drug3430 | Tocilizumab Wiki | 0.06 |
drug2490 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.80 |
D018410 | Pneumonia, Bacterial NIH | 0.35 |
D003139 | Common Cold NIH | 0.25 |
Name (Synonyms) | Correlation | |
---|---|---|
D008171 | Lung Diseases, NIH | 0.22 |
D003327 | Coronary Disease NIH | 0.18 |
D003324 | Coronary Artery Disease NIH | 0.18 |
D007676 | Kidney Failure, Chronic NIH | 0.16 |
D006331 | Heart Diseases NIH | 0.13 |
D006333 | Heart Failure NIH | 0.12 |
D020521 | Stroke NIH | 0.09 |
D011024 | Pneumonia, Viral NIH | 0.08 |
D009369 | Neoplasms, NIH | 0.06 |
D002318 | Cardiovascular Diseases NIH | 0.06 |
D012141 | Respiratory Tract Infections NIH | 0.06 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D014777 | Virus Diseases NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
D011014 | Pneumonia NIH | 0.04 |
D003141 | Communicable Diseases NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006536 | Pulmonary obstruction HPO | 0.94 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.72 |
HP:0002088 | Abnormal lung morphology HPO | 0.23 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001677 | Coronary artery atherosclerosis HPO | 0.18 |
HP:0001297 | Stroke HPO | 0.09 |
HP:0002664 | Neoplasm HPO | 0.07 |
HP:0011947 | Respiratory tract infection HPO | 0.06 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.06 |
HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 8 clinical trials
It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.
Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.
Measure: rate of recovery Time: 3 weeksDescription: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications
Measure: time to improvement Time: 3 weeksDescription: the efficacy of different pharmaceutical treatment against Covid-19
Measure: efficacy of treatments Time: 3 weeksDescription: liver, kidney or multiorgan failure, cardiac failure
Measure: organ failure Time: 3 weeksAn open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.
Measure: Dataset size Time: 14 daysDescription: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity
Measure: Cough sound identification Time: 14 daysDescription: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%
Measure: Improvement of the existing model Time: 14 daysDescription: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.
Measure: Evaluate the usability of the application Time: 14 daysThis phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsMolecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people.
Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.
Measure: Serology Time: 3 weeksDescription: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.
Measure: Efficacy of CT scan and Serology Time: 3 weeksDescription: the efficacy of different pharmaceutical treatments against Covid-19
Measure: Efficacy of different pharmaceutical treatments Time: 3 weeksBased on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19 (Corona Virus Disease-19).The aim of the study is to demonstrate in a double-blind, placebo-controlled approach if vaccination of participants susceptible to COVID-19 with BCG vaccine may modulate their disease susceptibility for COVID-19. This will be validated using both clinical and immunological criteria. At the same time, a sub-study will be conducted and the mechanism of benefit from BCG vaccination by assessing its effect on vascular endothelial function and mononuclear blood cells will be studied
Description: This is set on visit 3 (90 ± 5 days from the date of visit 1). The two groups of vaccination are compared for the primary endpoints which is composite. Patients who meet any of the following will be considered to meet the primary endpoint: Positive for the respiratory questionnaire endpoint when at least one of the following combination is met either at visit 2 and/or at visit 3: One situation definitively related to COVID-19 All four questions of symptoms possibly related to COVID-19 At least two questions of symptoms possibly related to COVID-19 as well as need for admission at the emergency department of any hospital and/or need for intake of antibiotics At least four questions of symptoms probably related to COVID-19 one of which is "need for admission at the emergency department of any hospital and/or need for intake of antibiotics" Positive IgG or IgM antibodies against SARS-CoV-2
Measure: Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3. Time: Visit 3 (90 +/- 5 days)Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint on visit 4
Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4 Time: Visit 4 (135 +/- 5 days)Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint (as defined at primary study endpoint) on visit 5
Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5 Time: Visit 5 (180 +/- 5 days)Description: Prevalence of IgG/IgM against SARS-CoV-2 will be measured among the patients who failed the eligibility procedure and the patients that were eligible and were enrolled
Measure: Prevalence of IgG/IgM against SARS-CoV-2 Time: Screening Visit and Visit 3 (90 +/- 5 days)Description: Itemized analysis of each of the components of the respiratory questionnaire on each study visit
Measure: Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19. Time: Visit 2 (45 +/- 5 days), Visit 3 (90 +/- 5 days), Visit 4 (135 +/- 5 days), Visit 5 (180 +/- 5 days)Description: The impact of new cardiovascular events between the two study groups (placebo and BCG) will be analyzed, though the collection of any cardiovascular events occured to the enrolled patients.
Measure: The impact of new cardiovascular events between the two study groups Time: Visit 2 (45 +/- 5 days), Visit 3 (90 +/- 5 days), Visit 4 (135 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Differences in repeated measurements of arterial stiffness in visit 3 between the two sub-study groups (placebo or BCG) will be analyzed through the speed of the pulse wave velocity. Pulse wave velocity is measured in m/sec.
Measure: Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 3 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)Description: Differences in repeated measurements of central arterial pressures and reflected waves in visit 3 between the two sub-study groups (placebo or BCG) will be measured non-invasively by pulse wave analysis. Central arterial pressure is measured in mmHg.
Measure: Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 3 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)Description: Differences in repeated measurements of endothelial function in visit 3 between the two sub-study groups (placebo or BCG) will be measured by ultrasound measurement of endothelium-dependent flow-mediated dilatation and by nitrate-mediated dialatation. Endothelial function will be assessed by Flow Mediated Dilatation (FMD). Endothelium-dependent: diameter of the artery prior and after temporary ischemia in is measured in mm, nitrate-mediated: diameter of the artery prior and after nitrate administration is measured in mm
Measure: Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 3 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)Description: Differences in repeated measurements of thickness of the medial carotid sheath in visit 3 between the two sub-study groups (placebo or BCG) will be measured by B-mode ultrasound examination. Intima-Media Thickness is measured in mm
Measure: Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 3 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)Description: Differences in repeated measurements of arterial stiffness in visit 5 between the two sub-study groups (placebo or BCG) will be analyzed through the speed of the pulse wave velocity. Pulse wave velocity is measured in m/sec.
Measure: Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 5 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Differences in repeated measurements of central arterial pressures and reflected waves in visit 5 between the two sub-study groups (placebo or BCG) will be measured non-invasively by pulse wave analysis. Central arterial pressure is measured in mmHg.
Measure: Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 5 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Differences in repeated measurements of thickness of the medial carotid sheath in visit 5 between the two sub-study groups (placebo or BCG) will be measured by B-mode ultrasound examination. Intima-Media Thickness is measured in mm
Measure: Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 5 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Differences in repeated measurements of endothelial function in visit 5 between the two sub-study groups (placebo or BCG) will be measured by ultrasound measurement of endothelium-dependent flow-mediated dilatation and by nitrate-mediated dialatation. Endothelial function will be assessed by Flow Mediated Dilatation (FMD). Endothelium-dependent: diameter of the artery prior and after temporary ischemia in is measured in mm, nitrate-mediated: diameter of the artery prior and after nitrate administration is measured in mm
Measure: Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 5 Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Differences in cardiac ultrasound at visit 5 between the two sub-study groups (placebo or BCG) will be assessed using standard measurements from 2-D and Doppler echocardiography.
Measure: Differences in cardiac ultrasound at visit 5 between the two sub-study groups Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)Description: Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups (placebo or BCG) will be analyzed
Measure: Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)exercise activity during the COVID pandemic is appreciated to be conducted in home especially for chronic chest diseases as chronic obstructive pulmonary disease (COPD) to reduce the chance of viral contamination during the COVID-19 pandemic.
Description: it will be measured in plasma
Measure: cortisol Time: It will be measured after eight weeks of trainingDescription: this a questionnaire that will assess anxiety and depression in COPD patients
Measure: hospital anxiety and depression scale Time: It will be measured after eight weeks of trainingDescription: it will be a measurement for lung volume and capacities
Measure: pulmonary function test Time: It will be measured after eight weeks of trainingDescription: It is an inflammatory marker in plasma
Measure: Interleukin-8 Time: It will be measured after eight weeks of trainingDescription: it will measure body mass changes
Measure: body mass index Time: It will be measured after eight weeks of trainingDescription: it assess functional capacity
Measure: six minute walking test Time: It will be measured after eight weeks of trainingDescription: It assess the effect of COPD on general quality of life
Measure: St. George's respiratory questionnaire Time: It will be measured after eight weeks of trainingThe purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.
Description: Change in forced expiratory volume in one second (FEV1) as compared to baseline, measured by home spirometer.
Measure: Change in forced expiratory volume in one second (FEV1) Time: Baseline and up to 90 DaysDescription: Changes in oxygen saturation from baseline as measured by pulse oximeter. Normal oxygen range is 95 to 100 percent and low oxygen range is under 90 percent.
Measure: Change in Oxygen Saturation level Time: Baseline and up to 90 DaysDescription: Changes in basal temperature as measured by digital thermometer. Fever is indicated at 100.4 F (38 C) or higher.
Measure: Change in Presence of Fever Time: Baseline and up to 90 DaysDescription: CAP Symptom Questionnaire records how much the patient rated the bothersomeness of the symptom. Each item is scored as "0" (Patient did not have this symptom), "1" (Not at All) to "5" (Extremely). Full range scale from 0 to 90, higher score indicating patient experiencing more frequent or more severe symptoms.
Measure: Change in Presence of pneumonia symptoms via Community Acquired Pneumonia (CAP) Symptom Questionnaire Time: Baseline and up to 90 DaysDescription: The QOL-B is a disease-specific questionnaire that measures symptoms, functioning, and health-related quality of life relevant to patients with bronchiectasis. Scores are generated from 37 items that fall on 8 domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms. All subscales and the full range scale are standardized to score from 0 to 100, with higher scores indicating better enjoyment and satisfaction with specific life domains.
Measure: Change in Quality of life via Quality of Life Questionnaire-Respiratory (QOL-B) Time: Baseline and up to 90 DaysDescription: The PHQ-8 is the depression module, which scores each of the eight DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-24, with higher score indicating more severe symptoms.
Measure: Change in Mental health screening via Personal Health Questionnaire Depression Scale (PHQ-8) Time: Baseline and up to 90 DaysDescription: The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire that asks user to rank how often they have been bothered by seven problems over the past two weeks from "0" (not at all) to "3" (nearly every day). Full scale from 0-21, with higher score indicating more symptoms.
Measure: Change in Mental health screening via General Anxiety Disorder-7 (GAD-7) Time: Baseline and up to 90 DaysDescription: Eight questions that are specific to recent literature describing patients' experiences of symptoms during COVID. They are rated on a frequency scale from "never" to "always," using a 1-4 point scale. Full scale range from 8 to 32, with higher scores indicating more frequent symptoms.
Measure: Change in COVID Symptom Checklist Time: Baseline and up to 90 DaysDescription: Amount of time used per week in minutes
Measure: AffloVest Usage Time: 90 DaysLeveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to continue telemedicine or telemedicine-supplemented care, rather than return to in-person care.
Description: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 12 months the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18), which is a 5-scale questionnaire including questions on patient satisfaction, communication quality with providers and accessibility/convenience of care.
Measure: Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: For individuals who accessed a telemedicine visit, we will ask questions based on the validated Telehealth Usability Questionnaire (TUQ), including the ease of use and access to the telemedicine service, quality of the interaction with the provider, and satisfaction
Measure: Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports